SNDX Overview
Upcoming Projects (SNDX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SNDX)
-
A Third Look: Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 22, 2024 at 04:00 PM EDT -
A Second Look: Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 22, 2024 at 03:00 PM EDT -
Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 17, 2024 at 03:00 PM EDT -
A third look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Oct 01, 2024 at 03:00 PM EDT -
A second look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Aug 22, 2024 at 05:00 PM EDT -
A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Aug 19, 2024 at 08:30 AM EDT -
A Third Look: Discussing the potential of Syndax Pharmaceuticals' axatilimab for pediatric and adult patients with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker: SNDX
Executed On: Dec 22, 2023 at 11:00 AM EST -
A Second Look: Discussing the potential of Syndax Pharmaceuticals' axatilimab for pediatric and adult patients with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker: SNDX
Executed On: Dec 22, 2023 at 09:00 AM EST -
Discussing the potential of Syndax Pharmaceuticals' axatilimab for pediatric and adult patients with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker: SNDX
Executed On: Dec 21, 2023 at 10:00 AM EST -
A Second Look: Understanding the potential of two drugs: SNDX-5613 (revumenib) by Syndax Pharma and Ziftomenib by Kura Oncology, both being developed for treating Acute Myeloid Leukemia with recent data released at the 2022 ASH Conference.
Tickers: SNDX, KURA
Executed On: Dec 21, 2022 at 08:30 AM EST -
Examining the potential of Syndax' Revumenib (SNDX-5613) in treating mNPM1 or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias
Ticker: SNDX
Executed On: Aug 19, 2022 at 11:00 AM EDT
Upcoming & Overdue Catalysts (SNDX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SNDX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
